Does iRhythm (IRTC) Balancing a Revenue Beat With In-Line Guidance Recast Its AI Cardiac Story?
iRhythm Technologies reported a quarterly revenue beat, exceeding analyst expectations by 2.8%, while reaffirming full-year guidance in line with consensus for its AI-enabled Zio cardiac monitoring platform. Despite the revenue beat, the muted investor reaction suggests the market was looking for stronger growth or profitability signals. This article examines how iRhythm's revenue performance and guidance could influence its investment narrative, especially concerning the adoption of AI-enabled cardiac monitoring and the company's path to sustainable profits.
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders of iRhythm stock to contact them to discuss potential legal options, which may include seeking corporate governance reforms or the return of funds to the company. The firm emphasizes that shareholder involvement can lead to improved company policies and enhanced shareholder value.
Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (IRTC) for alleged corporate wrongdoing. The firm encourages iRhythm stockholders who purchased securities before January 11, 2022, and continue to hold them, to assist in the investigation. Investors can find more information and connect with the firm through their website or by phone.
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
Kuehn Law, PLLC, a shareholder litigation law firm, is investigating iRhythm Technologies, Inc. (NASDAQ: IRTC) officers and directors for potential breaches of fiduciary duties. This investigation stems from a federal securities lawsuit alleging that iRhythm insiders misrepresented the Zio AT monitor's intended use and market potential, leading to artificially inflated stock prices. The firm encourages investors who bought IRTC prior to November 5, 2021, to contact them to discuss their rights.
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating whether officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties by allegedly misrepresenting the Zio AT monitor's intended use and market penetration. A federal securities lawsuit claims these misrepresentations led to artificially inflated stock prices. The firm encourages investors who purchased IRTC stock prior to November 5, 2021, to contact them for potential shareholder derivative litigation.
iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (IRTC) concerning possible corporate wrongdoing by its officers and/or directors. The law firm is encouraging investors who purchased iRhythm securities before January 11, 2022, and still hold them, to contact them to assist in the investigation. The firm operates on a contingency fee basis, meaning there is no cost to investors unless they are successful in recovering funds.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into iRhythm Technologies, Inc. (IRTC) for potential corporate wrongdoing, focusing on investors who purchased securities before January 11, 2022, and still hold them. The firm encourages affected stockholders to learn more and assist the investigation through their website. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Trading the Move, Not the Narrative: (IRTC) Edition
This article analyzes Irhythm Technologies Inc. (NASDAQ: IRTC), highlighting a potential shift in near-term positive sentiment and resistance testing. It outlines an exceptional short setup with a 71.5:1 risk-reward ratio, targeting 20.7% downside. The piece also details AI-generated institutional trading strategies for various risk profiles, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for IRTC.
Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (NASDAQ:IRTC) on behalf of investors who purchased securities before January 11, 2022, and continue to hold them. The investigation focuses on whether iRhythm and its officers engaged in corporate wrongdoing. The firm encourages affected shareholders to connect for more information, noting that their representation is on a contingency fee basis.
iRhythm Technologies | DEF 14A: Definitive information statements
This entry indicates the filing of a DEF 14A Definitive Information Statement by iRhythm Technologies. This document typically contains important information for shareholders regarding a company's annual meeting, including proposals to be voted on and details about executive compensation.
iRhythm Holdings (IRTC) Dropped Despite Posting Beat-And-Raise Results
Despite posting beat-and-raise results, iRhythm Holdings (IRTC) saw its stock drop, influenced by broader weakness in the healthcare equipment industry and investor rotation into cyclical and technology stocks. A US Department of Justice Civil Investigative Demand (DOJ CID) related to past mobile cardiac telemetry services also contributed to the pressure, although it is considered limited in scope. Carillon Eagle Small Cap Growth Fund noted the company's struggles in its Q1 2026 letter.
Cyberattacks on medtech companies become a frequent occurrence
Cyberattacks on medical technology companies are becoming increasingly common and sophisticated, targeting firms through methods like phishing and social engineering. iRhythm Technologies recently experienced a breach where data was stolen from third-party applications, prompting a ransom demand, though the company's core operations and patient safety were unaffected. This incident follows similar cyberattacks on Medtronic and Stryker, highlighting a growing trend of cybercriminals and state-linked groups targeting the medtech sector.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into iRhythm Technologies, Inc. (IRTC) for potential corporate wrongdoing, focusing on investors who purchased securities before January 11, 2022. The firm encourages these shareholders to participate in the investigation, which is conducted on a contingency fee basis. This aims to restore investor capital and ensure corporate accountability.
BTIG Keeps Their Buy Rating on Irhythm Technologies (IRTC)
BTIG analyst Marie Thibault maintained a Buy rating on Irhythm Technologies (IRTC) with a price target of $185.00, while the company's shares closed at $113.76. Thibault has an average return of -14.2% and a 33.40% success rate, and the analyst consensus for IRTC is a Strong Buy with an average price target of $177.36. Despite the positive analyst outlook, corporate insider sentiment on the stock is negative due to increased selling activity over the past quarter, including a recent sale of 1,716 shares by Sumi Shrishrimal, EVP & CRO.
iRhythm Technologies stock hits 52-week low at $101.50 By Investing.com
iRhythm Technologies Inc. (IRTC) stock has reached a 52-week low of $101.50, despite analysts predicting profitability this year and setting price targets between $147 and $255. The company recently reported strong Q1 fiscal 2026 revenues of $199 million, exceeding expectations and leading to updated price targets from several analysts, including Needham, Evercore ISI, Canaccord, and Oppenheimer. Despite the positive revenue performance, InvestingPro suggests the stock may be overvalued at current levels.
iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by iRhythm Technologies, Inc. (NASDAQ: IRTC). The firm is encouraging investors who purchased iRhythm securities before January 11, 2022, and continue to hold them, to contact them to assist with the investigation. This class action inquiry aims to recover investor capital and ensure corporate accountability.
iRhythm Technologies stock hits 52-week low at $101.50
iRhythm Technologies Inc. (IRTC) stock has fallen to a 52-week low of $101.50, despite predictions by analysts that the company will be profitable this year with price targets ranging from $147 to $255. The company recently reported strong first-quarter 2026 revenues of $199 million, surpassing expectations, and raised its 2026 revenue guidance, leading to some target adjustments by various analytical firms.
iRhythm Technologies stock hits 52-week low at $101.50 By Investing.com
iRhythm Technologies (IRTC) stock recently dropped to a 52-week low of $101.50, reflecting a significant decline over the past year. Despite this downturn, analysts anticipate profitability for the company this year, with price targets ranging from $147 to $255. Recent financial reports show strong first-quarter 2026 revenues exceeding expectations, leading to revised revenue guidance and mixed price target adjustments from various analysts.
iRhythm Technologies Inc (IRTC) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of iRhythm Technologies Inc (IRTC), listing its major institutional holders such as BlackRock and Vanguard, and categorizes shareholder types including investment advisors and hedge funds. It also provides historical institutional shareholding data and related ETF holdings.
iRhythm Technologies Inc (IRTC) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of iRhythm Technologies Inc (IRTC), detailing its current valuation score, P/E ratio, and market performance. As of June 18, 2026, IRTC's valuation score is 9.46, placing it 14th in the Healthcare Equipment & Supplies industry. The P/E ratio is -123.29, which is significantly below its recent high and above its recent low.
Hackers demand payment for stolen data tied to heart monitoring company iRhythm
Hackers have reportedly demanded payment for stolen data linked to iRhythm Holdings, a heart monitoring company. The cyberattack involved "social engineering" to gain access to patient records. This incident is being investigated by iRhythm Holdings and reported by the San Francisco Business Times.
IRhythm discloses data stolen from third-party applications in cyberattack
Cardiac monitoring company iRhythm disclosed that data, including proprietary information and patient health data, was stolen from third-party-hosted business applications in a cyberattack. A threat actor has demanded payment to prevent public disclosure of this information. While the attack did not affect iRhythm's clinical or medical device systems, the company is investigating the incident and believes it will not materially impact its financial condition.
iRhythm Technologies stock hits 52-week low at $101.50 By Investing.com
iRhythm Technologies (IRTC) stock recently dropped to a 52-week low of $101.50, trading slightly above this at $101.82, a significant decline from its 52-week high of $212. While the stock has seen a 29.28% decrease over the past year and InvestingPro suggests it is overvalued, analysts predict profitability this year with price targets ranging from $147 to $255. Recent Q1 2026 revenues of $199 million surpassed expectations, leading to revised revenue guidance and mixed price target adjustments from various analysts, who generally maintain Buy or Outperform ratings.
iRhythm Technologies Inc (IRTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for iRhythm Technologies Inc (IRTC), current as of April 6. It categorizes the company's revenue by business segments, including commercial payors, Centers for Medicare & Medicaid, healthcare institutions, and non-contracted third-party payors, highlighting the proportion each contributes to the total revenue.
iRhythm Technologies Inc (IRTC) Earnings Forecast: Future EPS & Revenue Growth Estimates
iRhythm Technologies Inc (IRTC) has an earnings forecast score of 8.80, ranking 10th in the Healthcare Equipment & Supplies industry. Analysts have a consensus "Buy" rating for IRTC, with an average target price of $220.00, suggesting a potential upside of 64.67%. The company's expected revenue for the next quarter is $219.29 million.
Cardiac Monitor Maker iRhythm Hit By Data Breach And Extortion Demand
iRhythm Technologies, a cardiac monitor manufacturer, has been affected by a data breach and an accompanying extortion demand. Despite the incident, the company has stated that it does not anticipate a material impact on its financial condition or operations. This event highlights the growing cybersecurity threats faced by healthcare companies.
iRhythm Technologies Data Breach Exposes Patient Information in Cardiac Monitoring Systems – June 2024 Cybersecurity Incident Analysis
iRhythm Technologies, a cardiac monitoring device provider, reported a data breach impacting patient information in June 2026. The breach, disclosed via a California DOJ filing, involved unauthorized access to unencrypted personal data such as names, Social Security Numbers, and medical details for over 500 California residents. While specific technical details of the attack are not yet public, the incident underscores significant risks to healthcare data and the regulatory obligations surrounding breach response and notification, leading to recommendations for enhanced security controls and incident response.
iRhythm Technologies Inc. disclosed in a filing with the U.S. Securities and Exchange Commission (SEC) that some compromised data was obtained through social engineering targeting a third-party application.
iRhythm Technologies Inc. has revealed to the U.S. SEC that some of its data was compromised through a social engineering attack on a third-party application. This incident underscores the cybersecurity risks within the digital medical data management supply chain. The company is currently evaluating the impact and has begun response and notification procedures.
iRhythm Hit by Cyberattack, Patient Data Stolen and Ransom Demanded
Digital healthcare company iRhythm, specializing in remote cardiac monitoring, disclosed a cyberattack where patient and proprietary data were stolen from third-party-hosted business applications. A threat actor has demanded a ransom for not publicly disclosing this information. The company's clinical and medical device systems, patient safety, operations, and customer connections were unaffected, and no payment card or financial account data was involved.
iRhythm Investigates Cyber Incident After Hackers Claim Access To Sensitive Data - iRhythm Holdings (NASD
iRhythm Holdings disclosed a cyber incident after hackers claimed to have accessed sensitive company and patient data, demanding payment. The company confirmed data exfiltration from third-party-hosted business applications but stated that core operations, products, and patient safety remain unaffected. An investigation is ongoing, and iRhythm maintains cybersecurity insurance, though it continues to assess the financial impact.
iRhythm Confirms Data Stolen in Hack
iRhythm, a health company specializing in wearable cardiac monitoring technology, has confirmed a cyberattack that led to the theft of sensitive information. The breach, detected on June 8, involved social engineering an unnamed third-party application, with attackers demanding a ransom for stolen proprietary data and patient health information. The company is actively investigating the extent of the data compromise and assured that its products, clinical systems, and financial reporting were not impacted.
iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. (NASDAQ:IRTC) who bought securities prior to January 11, 2022, and still hold them. The investigation focuses on whether the company and its officers engaged in corporate wrongdoing. Shareholders are encouraged to contact the firm to learn more and assist with the investigation.
(IRTC) Volatility Zones as Tactical Triggers
This article from Stock Traders Daily analyzes Irhythm Technologies Inc. (IRTC) using AI models to identify volatility zones and tactical triggers for trading. It presents various trading strategies (Position, Momentum Breakout, Risk Hedging) based on near-term, mid-term, and long-term signal analysis. The report highlights a significant 68.8:1 risk-reward short setup and divergent sentiment across different time horizons.
iRhythm reports cybersecurity breach with protected health data accessed
iRhythm (Nasdaq:IRTC) has disclosed a cybersecurity breach where unauthorized activity led to the exfiltration of proprietary data, patient protected health information, and other personal information from third-party-hosted business applications. A threat actor demanded payment to prevent public disclosure, but iRhythm stated that clinical or medical device systems were unaffected and the incident is not expected to materially impact its financial condition. This incident follows recent cyberattacks on other medtech companies like Stryker, Intuitive Surgical, and Medtronic.
iRhythm Technologies Inc. disclosed in a filing with the U.S. Securities and Exchange Commission (SEC) that some compromised data was obtained through social engineering targeting a third-party application.
iRhythm Technologies Inc. has informed the SEC about a data compromise stemming from a social engineering attack on a third-party application. This incident underscores
iRhythm Technologies Inc. disclosed in a filing with the U.S. Securities and Exchange Commission (SEC) that some compromised data was obtained through social engineering targeting a third-party application.
iRhythm Technologies Inc. has revealed in an SEC filing that compromised data was obtained through social engineering targeting a third-party application. This incident highlights supply chain security risks in digital medical data management. The company is currently evaluating the impact and has initiated response and notification procedures.
iRhythm Technologies Stock (US4627231087): Quarterly earnings remain the key focus for IRMD
iRhythm Technologies (IRMD) stock remains in focus for US investors, with its recent quarterly earnings and guidance on the Zio cardiac monitoring platform continuing to drive sentiment. The company's earnings narrative emphasizes revenue growth from Zio adoption, balancing growth investments with profitability, and navigating reimbursement changes. Investors will continue to analyze upcoming earnings reports for insights into the company
Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (NASDAQ:IRTC) on behalf of investors who purchased securities prior to January 11, 2022, and continue to hold them. The investigation aims to determine if iRhythm and its officers engaged in corporate wrongdoing. The firm encourages affected investors to contact them for more information and to assist in the investigation at no cost.
iRhythm Technologies (IRTC) Price Target Increased by 13.86% to 224.33
iRhythm Technologies (IRTC) has seen its average broker price target increase to $224.33, representing a 13.86% rise. This new target suggests a potential 22.09% upside from its last closing price, indicating a positive outlook from analysts. The current recommendation for IRTC is a Strong Buy.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (IRTC) regarding corporate wrongdoing. The investigation encourages investors who purchased iRhythm securities before January 11, 2022, and still hold them, to come forward. The law firm represents investors on a contingency fee basis and seeks to recover investor capital and ensure corporate accountability.
iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into iRhythm Technologies, Inc. (IRTC) concerning potential corporate wrongdoing. The firm is encouraging shareholders who purchased IRTC securities before January 11, 2022, and still hold them, to contact them to assist in the investigation. The representation of investors in class actions by Bronstein, Gewirtz & Grossman, LLC is on a contingency fee basis.
iRhythm Technologies Reaches $45 Million Securities Class Settlement
iRhythm Technologies (IRTC) has reached a binding $45 million settlement to resolve a securities class action lawsuit in the U.S. District Court for the Northern District of California. The settlement, which includes attorneys' fees and expenses, will result in dismissal with prejudice and a full release of claims, without any admission of fault. The company expects its directors and officers' insurance policies to cover most of the cost, and anticipates no material impact on its non-GAAP metrics.
IRhythm Inks $45M Deal With Investors In Heart Device Suit
IRhythm Technologies Inc. has reached a preliminary $45 million settlement with investors who alleged the digital healthcare company inflated stock prices through misrepresentations about its heart-event monitoring device. The investors have asked a California federal judge to approve the deal, citing it as a favorable outcome given the potential for no recovery if the case proceeded. The settlement aims to resolve claims that the company misled investors about the performance of its heart monitoring technology.
IRhythm Inks $45M Deal With Investors In Heart Device Suit
IRhythm Technologies Inc. has reached a preliminary $45 million settlement with investors who accused the digital healthcare company of inflating stock prices through misrepresentations about its heart-event monitoring device. The investors are seeking a California federal judge's approval for the deal, noting it's a favorable outcome given the litigation risks. The agreement aims to resolve allegations of stock price manipulation.
iRhythm reaches $45M settlement to resolve securities class action
iRhythm Technologies (IRTC) has announced a $45 million settlement to resolve a securities class action lawsuit against its subsidiary and CEO. The settlement, which includes legal fees and expenses, is expected to be largely covered by the company's D&O insurers, exhausting applicable policy limits. iRhythm anticipates that the settlement will not impact its adjusted EBITDA, adjusted net income (loss), or adjusted operating expenses.
iRhythm Holdings (NASDAQ: IRTC) agrees to $45M securities class action settlement
iRhythm Technologies, a subsidiary of iRhythm Holdings (NASDAQ: IRTC), has reached a binding Settlement Agreement to resolve a securities class action lawsuit for $45 million. The settlement, which includes legal fees, will result in the dismissal of all claims against the defendants without admission of fault. A majority of the payment is expected to be covered by the company's directors and officers insurance policies, and it is not anticipated to impact adjusted non-GAAP financial measures.
Price-Driven Insight from (IRTC) for Rule-Based Strategy
This article provides a price-driven analysis for Irhythm Technologies Inc. (NASDAQ: IRTC), indicating weak sentiment across all horizons that supports a short bias. It outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and specific entry/target/stop-loss levels. The analysis highlights an exceptional risk-reward setup targeting a 24.9% gain against a 0.3% risk.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against iRhythm Technologies, Inc. (IRTC) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into iRhythm Technologies, Inc. (NASDAQ:IRTC) regarding potential corporate wrongdoing, encouraging investors who purchased IRTC securities before January 11, 2022, and still hold them, to come forward. The firm, which specializes in securities fraud class actions, operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability. Affected stockholders are advised to visit the firm's website or contact their client relations team for more information.
IRhythm Technologies stock hits 52-week low at $108.19 By Investing.com
IRhythm Technologies (IRTC) stock has fallen to a 52-week low of $108.19, reflecting a 24.7% decrease over the past year and nearly 40% year-to-date. Despite analyst predictions of profitability this year, the stock is considered overvalued by InvestingPro. This downturn occurs amidst varied analyst price target adjustments following recent financial disclosures.
IRhythm Technologies stock hits 52-week low at $108.19 By Investing.com
IRhythm Technologies stock has fallen to a 52-week low of $108.19, reflecting a significant downturn for the company with a 24.7% decrease over the past year and nearly 40% year-to-date. Despite analyst predictions of profitability this year, InvestingPro analysis indicates the stock is currently overvalued. Analyst firms have adjusted price targets for iRhythm Technologies following recent financial disclosures, reflecting varied perspectives on its financial outlook and valuation.
